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ABSTRACT There are limited treatment options for immunosuppressed patients
with lethal invasive fungal infections due to Fusarium and Scedosporium. Manogepix
(MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme re-
quired for localization of glycosylphosphatidylinositol-anchored mannoproteins in
fungi. We evaluated the in vitro activity of MGX and the efficacy of the prodrug fos-
manogepix (APX001) in immunosuppressed murine models of hematogenously dissemi-
nated fusariosis and pulmonary scedosporiosis. The MGX minimum effective concentra-
tion (MEC) for Scedosporium isolates was 0.03g/ml and ranged from 0.015 to
0.03g/ml for Fusarium isolates. In the scedosporiosis model, treatment of mice with 78
mg/kg and 104mg/kg of body weight fosmanogepix, along with 1-aminobenzotriazole
(ABT) to enhance the serum half-life of MGX, significantly increased median survival time
versus placebo from 7days to 13 and 11 days, respectively. Furthermore, administration
of 104mg/kg fosmanogepix resulted in an 2-log10 reduction in lung, kidney, or brain
conidial equivalents/gram tissue (CE). Similarly, in the fusariosis model, 78mg/kg and
104mg/kg fosmanogepix plus ABT enhanced median survival time from 7days to 12
and 10 days, respectively. A 2- to 3-log10 reduction in kidney and brain CE was observed.
In both models, reduction in tissue fungal burden was corroborated with histopathologi-
cal data, with target organs showing reduced or no abscesses in fosmanogepix-treated
mice. Survival and tissue clearance were comparable to a clinically relevant high dose of
liposomal amphotericin B (10 to 15mg/kg). Our data support the continued develop-
ment of fosmanogepix as a first-in-class treatment for infections caused by these rare
molds.
KEYWORDS APX001, APX001A, Gwt1, antifungal, Fusarium, Scedosporium, infection
model, murine, manogepix, fosmanogepix, antifungal agents
Mycoses resulting from hyalohyphomycetes such as Scedosporium spp. and Fusar-ium spp. generally results in a poor prognosis, with the outcome related to the
degree and persistence of immunosuppression (1, 2). Scedosporiosis comprises a wide
range of clinical diseases, ranging from localized to disseminated infections in both
immunocompromised and immunocompetent hosts (3). Although rare, these infec-
tions are often difficult to treat with currently available antifungal agents. Mortality can
be as high as 80% in patients with invasive scedosporiosis, and Scedosporium apiosper-
mum is the leading cause of eumycetoma in North America and Western countries (4).
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Lomentospora prolificans (formerly Scedosporium prolificans) is generally highly resistant
to antifungal therapy, with mortality rates in immunocompromised patients similar to
those reported for S. apiospermum (3). Fusarium spp. are major causes of superficial
infections, including onychomycosis and keratitis, in immunocompetent individuals (5).
Fusariosis can also cause serious hematogenously disseminated infections in severely
immunocompromised patients, such as those with hematologic malignancies, which
are often associated with poor outcomes (6). Due to the rarity of scedosporiosis and
fusariosis, clinical trials for these diseases are problematic and the optimal antifungal
therapy is unclear. In addition to surgical debridement of the infected tissue, the
guidelines of the Infectious Diseases Society of America (IDSA) recommend voricona-
zole (VORI) or lipid-based amphotericin B (AMB) formulations as first-line therapy for
patients with severe Fusarium infections, with posaconazole (POSA) as salvage therapy
(7). Similarly, guidelines for Scedosporium include VORI or POSA as preferred agents for
first-line therapy, but notably, some organisms are resistant to AMB (7). However, even
with current standard-of-care treatments, patients with these diseases still have high
mortality (80 to 100%), especially those with prolonged immunosuppression (3, 4, 8).
More favorable clinical outcomes are generally associated with rapid diagnosis, surgical
debridement of the infection, improvement in neutrophil counts, and early use of
appropriate antifungal therapy, either alone or in combination. However, current
antifungal treatments are often associated with safety and toxicity issues. Thus, alter-
native treatment options are needed.
Fosmanogepix (APX001) is a broad-spectrum first-in-class small-molecule antifungal
that is currently in clinical development for the treatment of invasive fungal infections
(9). Fosmanogepix is an N-phosphonooxymethyl prodrug that is rapidly and completely
metabolized by host systemic phosphatases to the active moiety, manogepix (MGX;
formerly APX001A) (10). MGX targets the highly conserved fungal enzyme Gwt1, which
catalyzes an early step in glycosylphosphatidylinositol (GPI)-anchor biosynthesis (11).
Interestingly, the related mammalian ortholog, PIGW, is not sensitive to MGX inhibition
(12).
In a recent international SENTRY survey of 1,706 fungal clinical isolates from 2017,
MGX demonstrated activity against a wide range of pathogenic yeast and molds (13).
MIC90 values for yeasts were the following: Candida spp., 0.06 g/ml; Cryptococcus
neoformans, 0.5 g/ml. The MEC90 value for Aspergillus spp. was 0.03 g/ml. MEC values
ranged from 0.015 to 0.06 g/ml for 11 Scedosporium species isolates evaluated.
Similarly, a previous report showed that the MGX MEC90 values for S. apiospermum and
S. prolificans were 0.12 g/ml, and the MEC90 values for all Fusarium spp. evaluated
were 0.12 g/ml (67 strains) (14). The spectrum of MGX is notable for activity against
many less common but antifungal-resistant strains (13).
The efficacy of fosmanogepix has been demonstrated in multiple mouse models of
invasive pulmonary and disseminated fungal infections, including those caused by
Candida, Coccidioides, Cryptococcus, and Aspergillus spp. (15–18). In these studies,
treatment with fosmanogepix resulted in increased survival and reduced colony counts
of fungi in the lungs, kidney, and brain tissues of infected mice, as well as histological
improvement (10, 15–17, 19). Several of these studies involved preadministration of
1-aminobenzotriazole (ABT), a nonselective suicide inhibitor of cytochrome P450 (CYP)
enzymes (20), to increase the exposure and half-life of MGX in mice (17, 19). We have
previously shown that 50 mg/kg ABT administered 2 h prior to fosmanogepix enhanced
MGX exposures (area under the concentration-time curve [AUC]) 16- to 18-fold and
enhanced serum half-life from 1 to 9 h, more closely mimicking human pharmaco-
kinetic values (2 to 2.5 days) observed in phase 1 clinical studies in healthy volunteers
(9, 16, 21).
In this study, we assessed the in vitro activity of MGX against agents of scedospo-
riosis, lomentosporiosis, and fusariosis. We evaluated the efficacy of fosmanogepix, at
clinically relevant exposures, in two immunosuppressed murine models of (i) pulmo-
nary scedosporiosis and (ii) hematogenously disseminated fusariosis. In these studies,
we analyzed survival, tissue fungal burden as measured by a quantitative PCR (qPCR)
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assay, which assessed log10 conidial equivalents/gram tissue (CE), as well as histological
improvement.
RESULTS
Antifungal susceptibility. The activities of MGX and comparators were evaluated
against a panel of 6 Scedosporium, 3 Lomentospora prolificans, and 10 Fusarium clinical
isolates, including strains that were utilized in the efficacy models (Table 1). Suscepti-
bility was evaluated using the CLSI M38-A2 broth microdilution method for filamentous
fungi (22). The MGX MEC endpoint criteria were as described for the echinocandins. MIC
values were determined for the comparators VORI, POSA, and AMB. The range of MGX
concentrations evaluated in the antimicrobial susceptibility studies was 0.015 to 8.0 g/
ml. The MEC value of MGX was 0.03 g/ml for all individual Scedosporium and Lomen-
tospora isolates tested, including S. apiospermum DI16-478, used in the efficacy model.
The MEC value of MGX ranged from 0.015 g/ml to 0.03 g/ml for the 10 F. solani
isolates (Table 1). An additional 19 F. oxysporum strains were also evaluated, and all
isolates demonstrated MGX MEC values of 0.015 g/ml (data not shown). MIC90
values of comparator drugs for these strains were the following: 2 g/ml AMB, 8 g/ml
VORI, and 8 g/ml POSA (data not shown). These data are consistent with ranges of
MGX MEC values reported previously for Fusarium spp. (0.015 to 0.5 g/ml) and
Scedosporium spp. (0.03 to 0.25 g/ml) (14). The POSA and AMB MIC values against S.
apiospermum DI16-478 were 0.5 g/ml and 1.0 g/ml, respectively, whereas the VORI
and AMB MIC values against F. solani 95-2478 were 2 g/ml (Table 1).
Fosmanogepix demonstrates efficacy in a highly immunocompromised pulmo-
nary scedosporiosis model. To assess the effect of fosmanogepix in the treatment of
pulmonary scedosporiosis, ICR mice were immunosuppressed with cyclophosphamide
(200 mg/kg) and cortisone acetate (500 mg/kg) on days2 and3 relative to infection.
This treatment regimen results in 10 days of leukopenia with a total white blood cell
count dropping from13,0000/cm3 to almost no detectable leukocytes, as determined
by the Unopette system (BD, NJ) (23). Mice were intratracheally infected with 3 107
spores of S. apiospermum DI16-478 on day 0. This strain is susceptible to azoles as well
as to micafungin and previously has been validated in a neutropenic mouse model of
scedosporiosis (24). Treatment with placebo (diluent control), fosmanogepix (26, 52, 78,
or 104 mg/kg, orally [p.o.]), POSA (30 mg/kg twice a day [BID], p.o.), or liposomal
amphotericin B (L-AMB, 10 mg/kg, intravenous [i.v.]) began 16 h postinfection and
TABLE 1 Antifungal susceptibility profile of MGX and comparator agents
Clinical isolate
MIC/MEC (g/ml)
MGX POSA VORI AMB
Scedosporium apiospermum DI16-476 0.03 1.0 0.5 4.0
Scedosporium apiospermum DI16-477 0.03 0.5 NDb 2.0
Scedosporium apiospermum DI16-478a 0.03 0.5 1.0 1.0
Scedosporium boydii DI16-479 0.03 0.25 1.0 8.0
Scedosporium boydii DI16-480 0.03 2.0 1.0 4.0
Scedosporium boydii DI16-481 0.03 4.0 1.0 2.0
Lomentospora prolificans DI16-482 0.03 16 16 16
Lomentospora prolificans DI16-483 0.03 16 16 8
Lomentospora prolificans DI16-484 0.03 16 16 16
Fusarium solani 95-2478a 0.03 16 2 2
Fusarium solani DI19-284 0.015 4 2 1
Fusarium solani DI19-285 0.015 8 2 0.25
Fusarium solani DI19-286 0.015 16 16 1
Fusarium solani DI19-287 0.015 16 16 2
Fusarium solani DI19-288 0.015 16 16 0.5
Fusarium solani DI19-289 0.015 16 8 1
Fusarium solani DI19-290 0.015 16 16 2
Fusarium solani DI19-291 0.015 16 16 0.5
Fusarium solani DI19-292 0.015 16 16 2
aStrain used in the mouse infection model.
bND, not determined.
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continued daily for 7 or 11 days for fosmanogepix or POSA and 4 days for L-AMB. To
extend the half-life of MGX, 4 of the mouse cohorts were also administered 50 mg/kg
of the cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) 2 h prior to fosmano-
gepix administration, as previously described (19) and as labeled in Fig. 1 and Table 2.
(i) Survival. Survival of mice was assessed over 21 days (n 10 to 20 mice/cohort).
The median survival time for vehicle control cohorts with and without ABT were
equivalent (P 0.566): 7 and 8 days, respectively (Table 2). Neither POSA nor L-AMB
prolonged median survival time versus the placebo (P  0.5). In contrast, dosing
regimens of 52, 78, and 104 mg/kg fosmanogepix plus ABT for 7 days significantly
demonstrated prolonged median survival times of 17, 13, and 11 days, respectively
(Table 2 and Fig. 1). Of note is that the surviving mice looked healthy. Further, these
fosmanogepix treatments enhanced overall survival by day 21, when the experiment
was terminated (30% to 50% for 52 to 104 mg/kg versus 10% for placebo or POSA).
Survival after treatment with fosmanogepix for 7 days or 11 days was not different (data
not shown). Dosing regimens yielding lower exposures (26 mg/kg with ABT, 52 mg/kg
BID without ABT, and 104 mg/kg BID without ABT) did not result in statistically
significant prolonged median survival times (P 0.7, P 0.16, and P 0.36, respec-
tively) (Table 2 and Fig. 1), consistent with a dose response.
FIG 1 Survival of immunosuppressed mice infected with S. apiospermum DI16-478. ICR male mice (n 10 to 20) were infected
with an average inoculum of 3.0 107 spores of S. apiospermum DI16-478 per mouse via inhalation. Treatment was initiated
16 h after infection and continued daily for 7 days. A dose of 50 mg/kg ABT was administered orally 2 h prior to fosmanogepix
dose in all groups except the 52-mg/kg and 104-mg/kg (BID, without ABT) groups, as indicated. The nonparametric log-rank
test was used to determine differences in survival times. P values versus placebo (ABT) were 0.004 (**) and 0.05 (*); P values
versus placebo (without ABT) for POSA, L-AMB, and fosmanogepix (104 mg/kg and 52 mg/kg without ABT) did not achieve
statistical significance (P  0.16).
TABLE 2 S. apiospermum pulmonary infection median survival time
Treatmenta Median survival time (days) P value (versus placebo)
Placebo 8
Placebo (ABT) 7 0.566
Fosmanogepix
26 mg/kg (ABT) 10 0.07
52 mg/kg (ABT) 17 0.004
52 mg/kg (w/o ABT) 13 0.16
78 mg/kg (ABT) 13 0.04
104 mg/kg (ABT) 11 0.03
104 mg/kg BID (w/o ABT) 6 0.36
POSA, 30 mg/kg BID 8 0.08
L-AMB, 10 mg/kg 8 0.65
aw/o, without.
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(ii) Tissue burden. The effect of drug treatment on tissue fungal burdens was
examined using qPCR to evaluate log10 conidial equivalents (CE)/gram of tissue. Mice
(n 10) were infected and treated as in the survival studies and then sacrificed on day
4 (8 h after the last treatment), and lungs (primary target organ), kidneys, and brains
were processed and evaluated for CE/gram of tissue (25). In this experiment, we
evaluated several doses above the highest dose used in the survival study (104 mg/kg
plus ABT) in order to determine whether additional reductions in CE would be observed
at higher doses. These higher doses (156, 208, and 264 mg/kg, all plus ABT) can only be
used in studies in which mice are sacrificed at an early time point (e.g., 4 days) but not
in longer-term survival studies due to mouse-specific toxicity observed in highly
immunocompromised mice (18).
At all doses (104 to 264 mg/kg), fosmanogepix plus ABT significantly reduced tissue
fungal burden in lung (P  0.04) and brain (P  0.007) compared to that in placebo-
treated mice and were comparable to that of L-AMB treatment (P  0.18) (Fig. 2). In
kidney, all doses of 104 mg/kg to 264 mg/kg plus ABT significantly reduced fungal
burden compared to placebo control (P 0.007), but only the highest dose (264 mg/kg
plus ABT) demonstrated statistical significance versus L-AMB treatment (P 0.02) (Fig.
2). Thus, a dose-response curve generally was not observed at these higher dosing
levels. All fosmanogepix treatments resulted in an 2-log reduction in lung, brain, and
kidney CE.
(iii) Histological observations. Brain tissues taken from placebo mice processed at
the same time of the tissue fungal burden experiment (4 cohorts of 104, 156, 208, and
264 mg/kg plus ABT) and collected at day4 postinfection (n 3 mice/group) showed
that S. apiospermum spores had disseminated from the lungs to the brain with
fulminant growth and inflammation (Fig. 3) that coincided with neurological symptoms,
including torticollis, spinning, and barrel rolling. In contrast, no signs of infection or
inflammation could be detected in any of the brains collected from mice treated with
fosmanogepix (104 to 264 mg/kg plus ABT) or L-AMB (10 mg/kg) (Fig. 3). These results
confirm the similar efficacy of fosmanogepix and L-AMB in this scedosporiosis murine
model. Surprisingly, we could not detect any signs of infection in the lung (the primary
infection target), indicating the rapid dissemination of the infection to the brain and/or
lack of fungal filamentation in this organ (data not shown).
Fosmanogepix demonstrates efficacy in an immunocompromised dissemi-
nated fusariosis model. We investigated the efficacy of fosmanogepix in the treat-
FIG 2 Reduction in tissue burden in the pulmonary scedosporiosis model. Tissue burdens in mice (10 per group) were measured at 4 days
postinfection with S. apiospermum DI16-478. Male ICR mice were infected with 3.0 107 spores via inhalation. Treatment was initiated
16 h postinfection and continued for 4 days. ABT (50 mg/kg) was administered orally 2 h prior to daily fosmanogepix dosing. Mice were
sacrificed 8 h after the last dose, and lung, kidney, and brain were harvested and processed for tissue fungal burden by qPCR. P values
are shown versus placebo control. None of the other intergroup comparisons reached statistical significance except for reduction in kidney
burden for 264 mg/kg fosmanogepix (plus ABT) versus 10 mg/kg L-AMB (P 0.02). Conidia Equ, conidia equivalents.
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ment of disseminated fusariosis, as previously described (26). Immunosuppression of
ICR mice was performed as described above for the scedosporiosis model. Mice were
infected with 8.1 102 spores of F. solani 95-2478 (MEC, 0.03 g/ml) by tail vein
injection on day 0. This strain was from a patient blood sample and was previously used
in neutropenic mouse models of disseminated fusariosis (26, 27). Treatment with
placebo (diluent control), fosmanogepix (78 or 104 mg/kg, p.o.) plus 50 mg/kg ABT,
L-AMB (15 mg/kg, i.v.), or VORI (40 mg/kg, p.o.) began 16 h postinfection and continued
for 8 days for fosmanogepix or VORI and 4 days for L-AMB. To enhance the half-life of
the molecules, 50 mg/kg ABT was administered 2 h prior to fosmanogepix, and
grapefruit juice (50%) was added in the drinking water for VORI-treated mice (28). Mice
were sacrificed on day 4 and organs processed to determine CE by qPCR.
(i) Survival. Treatment of mice (n 10/group) with fosmanogepix plus ABT or
L-AMB significantly (P  0.01) enhanced median survival time versus placebo (12 and
10 days for 78 and 104 mg/kg of fosmanogepix, 10 days for L-AMB treatment) (Table 3).
Furthermore, fosmanogepix plus ABT and L-AMB treatments equally enhanced overall
survival by day 21 when the experiment was terminated (40% for L-AMB or fosmano-
gepix at 78 mg/kg and 20% for fosmanogepix at 104 mg/kg) (Fig. 4). VORI was not
effective in this model in terms of median survival time or overall survival by day 21
(Table 3 and Fig. 4).
(ii) Tissue burden. Administration of L-AMB (15 mg/kg) and fosmanogepix (78 mg/
kg, 104 mg/kg, and 130 mg/kg) plus ABT resulted in reductions in tissue burden CE that
were statistically different from values for the placebo control (kidney, P  0.0003;
brain, P 0.0154) (Fig. 5) (n 10/group). Compared to placebo, treatment with 78, 104,
or 130 mg/kg fosmanogepix plus ABT reduced kidney counts by 2.10, 2.21, and 3.14
log10 CE, respectively, while L-AMB treatment resulted in a 3.96-log10 reduction in
FIG 3 Histological examination of brain harvested from mice infected with S. apiospermum and treated with
placebo, fosmanogepix, or L-AMB. Mice were infected and treated as described for Fig. 2. Harvested fixed brains
were stained with GMS prior to microscopic examination. Notice the intact hyphae in the placebo control group.
Treatment with fosmanogepix plus ABT or L-AMB resulted in normal brain architecture with no signs of fungal
dissemination.
TABLE 3 F. solani hematogenously disseminated infection model median survival times
Treatment Median survival time (days) P value (versus placebo)
Placebo 7
Fosmanogepix, 78 mg/kg 12 0.002
Fosmanogepix, 104 mg/kg 10 0.01
VORI, 40 mg/kg 8 0.42
L-AMB, 15 mg/kg 10 0.001
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kidney counts. L-AMB demonstrated activity that was equivalent to 130 mg/kg fos-
manogepix in reduction of kidney CE (P 0.3). Compared to placebo, treatment with
78, 104, or 130 mg/kg fosmanogepix plus ABT reduced brain counts by 2.10, 2.58, and
3.04 log10 CE, respectively, versus 3.76 log10 for L-AMB. L-AMB demonstrated activity
that was statistically equivalent to both 104 mg/kg and 130 mg/kg fosmanogepix in
reduction of brain CE (P  0.07). VORI did not demonstrate statistically significant
reductions in CE versus placebo control in brain (0.48 log10 CE) or kidney (0.68 log10 CE),
and fosmanogepix outperformed this azole in treating hematogenously disseminated
murine fusariosis (Fig. 5).
(iii) Histological observations. Kidney tissues that were harvested from a parallel
tissue burden experiment that utilized dosing regimens of 78, 104, and 130 mg/kg
fosmanogepix (plus ABT) and 15 mg/kg L-AMB were also processed for histology (n 3
mice/group). Consistent with the tissue fungal results, kidneys from placebo- or VORI-
treated mice showed diffused and fulminant filamentation of F. solani (Fig. 6). In
FIG 4 Survival of immunosuppressed mice infected with F. solani. ICR male mice (n 10) were infected
with an inoculum of 8.1 102 spores per mouse via vein infection. Treatment was initiated 16 h after
infection and continued daily for 8 days. Grapefruit juice (50%) was added into the drinking water of the
VORI treatment group from day 2 to day 4 to enhance the drug half-life; 50 mg/kg ABT was
administered daily 2 h prior to fosmanogepix dosing. *, P  0.05; **, P  0.002. P values were assessed
versus the placebo control using the log rank test.
FIG 5 Reduction in kidney and brain tissue burden in a disseminated Fusarium model. Mouse kidney and brain
tissue burdens in mice (n 10) were measured at 4 days postinfection. Male ICR mice were infected and treated
as described for Fig. 4 with a dose of 50 mg/kg ABT administered orally 2 h prior to daily fosmanogepix dosing.
Mice were sacrificed 8 h after the last dose, and kidney and brain tissues were harvested and processed for fungal
burden by qPCR. Fungal burden data (presented as medians 	 interquartile ranges) were log10 transformed and
evaluated using the nonparametric Wilcoxon rank sum test (Prism 5; GraphPad Software, Inc., San Diego, CA). P
values are shown versus placebo control. (A and B) Intergroup comparisons. (A) For kidney, 130 mg/kg fosmano-
gepix was equivalent to L-AMB (P 0.2853), and they both had P values of 0.05 (*) versus all other groups. (B)
For brain, 130 mg/kg fosmanogepix, 104 mg/kg fosmaogepix, and L-AMB were equivalent (P  0.06) and had P
values of 0.05 (**) versus all other groups.
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contrast, less diffusion of fungal hyphae was evident in kidneys treated with fosmano-
gepix at 78 mg/kg, while fungal elements were confined to a small abscess in kidneys
treated with fosmanogepix at 104 mg/kg. Finally, kidneys harvested from mice treated
with fosmanogepix at 130 mg/kg or L-AMB at 15 mg/kg had similar and consistently
less infection than other groups (Fig. 6).
DISCUSSION
There are limited treatment options for the management of hyalohyphomycosis,
especially in the case of disseminated disease in highly immunocompromised patients.
Fosmanogepix is an i.v. and orally available antifungal prodrug that is currently in
clinical development for the treatment of life-threatening invasive fungal infections,
including candidiasis and aspergillosis. The broad-spectrum nature of this first-in-class
agent previously has been demonstrated in vitro as well as in vivo (15–18).
A previous study evaluated the efficacy of fosmanogepix in the treatment of
disseminated fusariosis and pulmonary scedosporiosis using less immunocompromised
models where 200 mg/kg of 5-fluorouracil was administered 5 or 6 days prior to
infection (29). In the two survival experiments, the nadir of the neutrophil counts
occurred approximately on the day of infection (30), with neutrophils recovering early
during the course of the infection. The current regimen results in pancytopenia for at
least 9 days from the first administered dose (23).
In this study, successful treatment outcomes utilized ABT plus oral dosing of
78 mg/kg or 104 mg/kg fosmanogepix, where total area under the plasma drug
concentration-time curve (tAUC) values were 200 and 280 g·h/ml (K. J. Shaw,
unpublished), exposures that were shown in pharmacokinetic/pharmacodynamic (PK/
PD) studies to be associated with A. fumigatus stasis and 1-log kill, respectively (31). To
achieve 90% survival in the earlier study that utilized 5-fluorouracil with three-times-
per-day (TID), intraperitoneal (i.p.) administration dosing regimens (without ABT) re-
sulted in total tAUC values that ranged from 12 g·h/ml (fusariosis) to 46 g·h/ml
(scedosporiosis), considerably lower than the exposures needed for efficacy in the
current study, where animals were severely immunocompromised with a cyclophos-
phamide-cortisone acetate regimen. Consistent with the increased severity of the
current model, fosmanogepix dosed at 104 mg/kg BID without ABT (tAUC of50 g·h/
ml; Shaw, unpublished) did not result in statistically significant prolonged median
survival times in the scedosporiosis model.
FIG 6 Histological examination of kidney tissue harvested from mice infected with F. solani and treated with
placebo, fosmanogepix, VORI, or L-AMB. Mice were infected and treated as described for Fig. 5. Notice the diffused
and fulminant filamentation in kidney tissue of F. solani in placebo- or VORI-treated mice. Fewer hyphae are evident
in kidneys of mice treated with fosmanogepix or L-AMB.
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In terms of clinical relevance, the exposures reached in the current study (200 and
280 g·h/ml) are consistent with exposures achieved in fosmanogepix phase 1 single-
and multiple-ascending-dose studies (9, 21) and anticipated in future fosmanogepix
clinical trials. Efficacy, as measured by median survival time versus placebo control, was
observed in both the S. apiospermum pulmonary infection model and the F. solani
disseminated model using both of these dosing regimens (P  0.05).
Although clinical guidelines for Scedosporium include VORI as the preferred agent
for first-line therapy (7), the data from the pulmonary scedosporiosis model showed
that there was no benefit in overall survival or in median survival time versus the
placebo control (P  0.08) of mice treated with a high dose of POSA (30 mg/kg BID),
which resulted in exposures in mice that are approximately six times the clinically
relevant dose (32). Of note is that this high dose of POSA was efficacious in a pulmonary
aspergillosis model (18), highlighting the difficulty of successful treatment of pulmo-
nary scedosporiosis despite the POSA MIC value against both molds being 0.5 g/ml
(Table 1) (18). Similarly, a high dose of 10 mg/kg L-AMB, which is typically used in
invasive mold infection models as a comparator, was ineffective in extending survival
in this model versus the placebo control (P  0.65).
In the disseminated fusariosis model, the control antifungal agents utilized were also
consistent with first-line standard of care for patients. In a previous study, Graybill et al.
utilized grapefruit juice to enhance the half-life of VORI, resulting in the observation of
prolonged survival and reduced numbers of CFU in a disseminated F. solani 95-2478
model when 10 mg/kg or 20 mg/kg VORI was administered (28). However, in this study,
40 mg/kg VORI plus grapefruit juice was not efficacious (P  0.42). Although the same
strain of F. solani and the same strain of mice (ICR) were used in the two studies, there
are notable differences in the two experiments. The Graybill et al. study utilized a 3-log
higher inoculum (8 105 CFU/mouse versus 8.1 102/mouse); however, the mice were
immunocompromised with 150mg/kg 5-fluorouracil on day 1 rather than utilizing the
cyclophosphamide-cortisone acetate regimen utilized here. Consistent with the increased
level of immunosuppression of the current model, the higher dose (40mg/kg) of VORI was
not effective in the current model. In contrast, in this study, mice administered a high dose
of 15mg/kg L-AMB demonstrated survival that was significantly different from that of the
placebo control (P  0.001) and was equivalent to fosmanogepix dosed at 78 and
104mg/kg plus ABT (P  0.5).
Histology and CFU number reduction were also evaluated in the S. apiospermum
and F. solani models using dosing regimens that were of concentrations equal to or
higher than those used in the survival study in order to determine whether greater
organism clearance would be observed at higher doses. Compared to placebo control
mice in the pulmonary scedosporiosis model, all doses of 104 mg/kg to 264 mg/kg
fosmanogepix plus ABT resulted in a significant reduction in brain, lung, and kidney
burdens. At these higher doses, no clear dose response was observed, since there was
no significant difference between the fosmanogepix treatment regimens when evalu-
ated pairwise, suggesting that maximal activity was achieved at the dose of 104 mg/kg
fosmanogepix plus ABT or was outside the dynamic range of the assay.
Consistent with the survival results using the disseminated fusariosis model, com-
pared to the placebo control group, significant reductions in brain and kidney fungal
burden were observed for fosmanogepix (78 mg/kg, 104 mg/kg, and 130 mg/kg) plus
ABT and 15 mg/kg L-AMB but not for VORI. In brain, again no statistical significance was
observed between fosmanogepix dosing groups; however, kidney burden was statis-
tically lower for the highest fosmanogepix dosing group (130 mg/kg) and equivalent to
that for L-AMB. The activity of fosmanogepix was also confirmed by the lack of
detection of any fungal elements in the brains of mice with scedosporiosis and with the
reduced fungal elements seen in kidneys of mice infected with F. solani.
In this study, we showed that the active moiety MGX was highly active against S.
apiospermum, S. boydii, L. prolificans, and F. solani in vitro. Using highly immunocom-
promised mouse models of pulmonary scedosporiosis and disseminated fusariosis, we
demonstrated that the efficacy of fosmanogepix was equivalent to or better than the
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current standard of care of antifungal agents. Findings from both oral and i.v. fosmano-
gepix phase 1 clinical studies have shown favorable PK, allowing once-daily dosing with
high bioavailability (90%) and no food effect (9, 21). Given the previous demonstra-
tion of efficacy across a broad range of yeasts and mold mouse models, including
Candida (15, 16, 19) and Aspergillus (18, 31), activity against azole- and echinocandin-
resistant isolates of Aspergillus species (Cyp51 and Fks1, respectively) (31), as well as the
data described here for Fusarium and Scedosporium, further investigations into the
development of this first-in-class agent for invasive fungal infections is highly war-
ranted, especially against difficult-to-treat infections.
MATERIALS AND METHODS
Microorganisms. Nine clinical isolates of Scedosporium/Lomentospora and 9 clinical isolates of
Fusarium solani were obtained from the Fungus Testing Laboratory at the University of Texas Health
Sciences Center at San Antonio (UTHSCSA) (Table 1). Fusarium solani 95-2478 is a blood isolate provided
by P. Ferrieri (University of Minnesota) (26). Fungal strains used in this study were routinely grown on
Sabouraud dextrose agar plates for 5 to 10 days until confluent at 37°C. Conidia were collected by
flooding the plates with sterile phosphate-buffered saline containing 0.01% (vol/vol) Tween 80. The
conidia were concentrated by centrifugation and washed in the same buffer, diluted, and counted using
a hemocytometer.
Antifungal agents. For in vitro studies, the active moiety MGX (Amplyx Pharmaceuticals) was used
along with AMB (Fisher Scientific, Hampton, NH), POSA (Sigma-Aldrich Corp., St. Louis, MO, USA), and
VORI (Sigma-Aldrich Corp., St. Louis, MO, USA). For efficacy studies, the water-soluble N-phospho-
nooxymethyl prodrug fosmanogepix (Amplyx Pharmaceuticals) was used. The final prodrug solution was
in 5% dextrose and dosed orally (p.o.) per gram of mouse body weight. A 5-mg/ml solution of ABT (Fisher
Scientific, Hampton, NH) in water was administered orally 2 h prior to infection as 10 l per gram of
mouse body weight, resulting in a dose of 50 mg/kg, and this served as the placebo plus ABT group. For
in vivo efficacy studies, POSA (Merck & Co., Inc., Rahway, NJ) was purchased as an oral suspension
(200 mg/5 ml) and kept at room temperature. L-AMB (Gilead Science, Foster City, CA) and VORI (50-mg
tablet from Ajanta Pharma USA, Bridgewater, NJ) were obtained from local pharmacies. The final L-AMB
solution was dissolved in 5% dextrose and administered intravenously, while crushed VORI tablets were
suspended in irrigation water and administered to mice by oral gavage.
In vitro testing. The in vitro susceptibility of manogepix (drug concentrations of 0.015 to 8.0 g/ml)
against agents of scedosporiosis and fusariosis was evaluated using the Clinical Laboratory and Stan-
dards Institute (CLSI) M38-A2 method using minimum effective concentration (MEC) endpoints for the
echinocandins (22). Three clinical isolates each of Scedosporium apiospermum, S. boydii, and Lomento-
spora prolificans were evaluated along with 10 strains of F. solani. MIC values were determined for POSA,
VORI, and AMB (22). All in vitro testing was conducted with drug powders with known potencies.
Efficacy models. ICR mice (Envigo) were immunosuppressed with cyclophosphamide (200 mg/kg)
and cortisone acetate (500 mg/kg) on days 2 and 3 relative to infection (n 10/group). To prevent
bacterial infection, enrofloxacin (50 g/ml) was added to the drinking water from day 3 to day 0.
Ceftazidine (5 g/dose/0.2 ml) replaced Baytril treatment on day 0 and was administered daily by
subcutaneous injection from day 0 until day 8. All drug treatments were initiated 16 h postinfection
and continued for 8 consecutive days, given by oral gavage for POSA, VORI, or fosmanogepix, but L-AMB
was given intravenously through day 4. To extend the half-life of MGX, mice were administered
50 mg/kg the cytochrome P450 inhibitor ABT 2 h prior to fosmanogepix administration for most of the
cohorts. The prodrug fosmanogepix was dosed at 26 mg/kg (with ABT), 52 mg/kg (with and without ABT),
78 mg/kg (with ABT), 104 mg/kg (with and without ABT), 156 mg/kg (with ABT), 208 mg/kg (with ABT),
and 264 mg/kg (with ABT) in the various experiments. Using a conversion factor of 1.3 to account for the
methyl phosphate group in the prodrug, the doses were equivalent to MGX at 20 mg/kg, 40 mg/kg,
60 mg/kg, 80 mg/kg, 120 mg/kg, 160 mg/kg, and 203 mg/kg, respectively.
(i) Pulmonary S. apiospermum. The immunosuppressed mice were challenged with 3.0 107
spores of S. apiospermum DI16-478 through intratracheal instillation of 25 l after sedation with
isoflurane gas (33). Immediately after infection, a subset of mice was sacrificed and lungs were removed to
determine infection inoculum by quantitative culturing (n 10/group). For S. apiospermum survival studies,
treatment with placebo (diluent control), fosmanogepix (26, 52, 78, or 104 mg/kg, p.o.), POSA (30mg/kg, BID
or p.o.; representing 6 times the human equivalent dose [32]), or L-AMB (10mg/kg, i.v.) begun 16 h
postinfection and continued for 7 days for fosmanogepix or POSA and 4 days for L-AMB. Mice weremonitored
for 21 days. To assess tissue fungal burden, mice were sacrificed on day4 and organs processed for conidial
equivalents (CE) by qPCR using actin primers (forward [F], CCCTTGACTTTGAGCAGGAG; reverse [R], CTCAAG
ACCGAGGACAGAGG). Mouse DNA was detected with the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) primers (F, AGGCAACTAGGATGGTGTGG; R, TTGATTTTGGAGGGATCTCG).
(ii) Disseminated F. solani. Mice were infected with a targeted inoculum of 8.1 102 cells of F.
solani by tail vein injection. For survival studies, treatment with placebo (diluent control), fosmanogepix
(78 or 104 mg/kg, p.o.) plus ABT, L-AMB (15 mg/kg, i.v.), or VORI (40 mg/kg, p.o.) began 16 h postinfection
and continued for 8 days for fosmanogepix or VORI and 4 days for L-AMB (n 10/group). To enhance the
half-life of VORI, grapefruit juice (Ocean Spray) was added to the drinking water to a final concentration
of 50% and was given to VORI-treated mice. To assess tissue fungal burden, mice were infected and
treated as described above, except that mice were sacrificed on day 4 (4 days of treatment), 8 h
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following the last treatment (n 10/group). Organs were processed for CE by qPCR using 28S primers
(F, TAAATGGACCAGGGCGCAAA; R, AGAGGGAACGAGATGGGTT).
For both models, tissues harvested from mice to assess fungal burden were also processed for
histopathological examination. Briefly, tissues were fixed in 10% zinc-buffered formalin, paraffin embed-
ded, sectioned, and stained with Grocott’s methenamine silver (GMS) stain for microscopic examination
(n 3/group).
Statistical analysis. The nonparametric log rank test was used to determine differences in survival
times. Differences in lung, kidney, and brain CFU numbers were compared by the nonparametric
Wilcoxon rank sum test. A P value of 0.05 was considered significant.
All animal-related study procedures were compliant with the Animal Welfare Act, the Guide for the
Care and Use of Laboratory Animals (34), and the Office of Laboratory Animal Welfare and were conducted
under an IACUC-approved protocol by The Lundquist Institute at Harbor-UCLA Medical Center.
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